In patients with chronic myeloid leukaemia (CML) in chronic phase (CP) who have not achieved molecular response with first-line imatinib at 3 months, early switching to dasatinib increases the chances of achieving major molecular response (MMR) at 12 months, according to data from the phase IIb DASCERN trial.
Comprehensive recommendations on coronavirus disease 2019 (COVID-19) for cancer patients have become available following review of guidelines from 63 national/international oncology societies. [Lancet Oncol 2020, doi: 10.1016/S1470-2045(20)30278-3]
The allosteric inhibitor asciminib shows clinical activity in heavily pretreated patients with chronic myeloid leukaemia who have failed or cannot tolerate tyrosine kinase inhibitors, including those who do not respond to ponatinib and harbour a T315I mutation, according to the results of a phase I dose-escalation study.
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.
Use of imatinib in the first-line treatment of children and adolescents with chronic myeloid leukaemia (CML) appears highly effective, yielding excellent response with tolerable side effects, according to the results of a single-arm phase III trial.
Use of bosutinib in the treatment of chronic myeloid leukaemia (CML) still proves to be more effective than imatinib, with a higher major molecular response rate, according to the 24-month follow-up data from the phase III BFORE* trial.
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.